Clene (CLNN) closed at $3.92 on November 13, 2026, down 2.0% from the previous close, on volume of 28,733 shares (30-day average 95,551).
Data as of November 13, 2026.
13-Nov-2026
Clene’s Regulatory Catalyst and RESTORE-ALS Potential Support Buy Rating; $30 Price Target Unchanged
TipRanks (Thu, 12-Nov 8:15 AM ET)
Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights
Globe Newswire (Wed, 4-Nov 8:30 AM ET)
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
Globe Newswire (Mon, 19-Oct 8:00 AM ET)
Clene to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 22-Sep 8:00 AM ET)
Globe Newswire (Mon, 21-Sep 8:30 AM ET)
Clene Announces $4 Million Registered Direct Offering
Globe Newswire (Tue, 15-Sep 9:00 AM ET)
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Globe Newswire (Tue, 8-Sep 8:30 AM ET)
Clene to Present at Upcoming September Investor Conferences
Globe Newswire (Thu, 3-Sep 8:00 AM ET)
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
Globe Newswire (Wed, 19-Aug 7:00 AM ET)
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream
Globe Newswire (Tue, 18-Aug 7:00 AM ET)
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Clene trades on the NASDAQ stock market under the symbol CLNN.
As of November 13, 2026, CLNN stock price declined to $3.92 with 28,733 million shares trading.
CLNN has a beta of 2.20, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.07 to the broad based SPY ETF.
CLNN has a market cap of $56.45 million. This is considered a Micro Cap stock.
Last quarter Clene reported $56,000 in Revenue and $.05 earnings per share. This fell short of revenue expectation by $-9,360 and exceeded earnings estimates by $.52.
In the last 3 years, CLNN traded as high as $13.50 and as low as $2.28.
The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF, IWC.
CLNN has underperformed the market in the last year with a return of -46.3%, while the SPY ETF gained +13.4%. In the last 3 month period, CLNN fell short of the market, returning -6.4%, while SPY returned -2.8%. However, in the most recent 2 weeks CLNN has outperformed the stock market by returning +2.3%, while SPY returned -0.2%.
CLNN support price is $3.72 and resistance is $4.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.